What's killing pa­tients in Bay­er's Xofi­go com­bo study? Re­searchers un­blind study ear­ly to probe safe­ty alert

Back in the spring of 2016, re­searchers re­port­ed that a com­bi­na­tion of Bay­er’s Xofi­go (ra­di­um-223) with Zyti­ga (abi­raterone) came through with ev­i­dence of sig­nif­i­cant­ly re­duced …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.